Vertex reports fourth quarter and full year 2023 financial results

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today reported consolidated financial results for the fourth quarter and full year ended december 31, 2023 and provided full year 2024 financial guidance. “2023 was a transformative year for vertex as we continued our strong performance, including 11% revenue growth, combined with significant advancement across the business. we expanded our leadership in cf, diversified our commercial opportunity with casgevy regulatory.
VRTX Ratings Summary
VRTX Quant Ranking